These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 26688036)

  • 41. In vitro Controlled Release of two new Tuberculocidal Adamantane Aminoethers from Solid Pharmaceutical Formulations (II).
    Vlachou M; Siamidi A; Spaneas D; Lentzos D; Ladia P; Anastasiou K; Papanastasiou I; Foscolos AS; Georgiadis MO; Karalis V; Kellici T; Mavromoustakos T
    Drug Res (Stuttg); 2017 Nov; 67(11):653-660. PubMed ID: 28724167
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Quick and Simultaneous Analysis of Dissolved Active Pharmaceutical Ingredients and Formulation Excipients from the Dissolution Test Utilizing UHPLC and Charged Aerosol Detector.
    Kimoto M; Sakane T; Katsumi H; Yamamoto A
    AAPS PharmSciTech; 2021 Nov; 22(8):262. PubMed ID: 34725748
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Correlating cellulose derivative intrinsic viscosity with mechanical susceptibility of swollen hydrophilic matrix tablets.
    Klančar U; Horvat M; Baumgartner S
    AAPS PharmSciTech; 2012 Sep; 13(3):903-10. PubMed ID: 22711256
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A novel spectroscopic analysis to detect photochemical reaction of the bronchodilator - Doxofylline and its estimation in pharmaceutical formulation.
    Sasi Rekha P; Gunasekaran S
    Spectrochim Acta A Mol Biomol Spectrosc; 2018 Feb; 190():140-149. PubMed ID: 28922640
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Formulation, development, and
    El-Enin ASMA; Elbakry AM; Hosary RE; Lotfy MAF
    Pharm Dev Technol; 2020 Oct; 25(8):989-998. PubMed ID: 32397780
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mechanistic Insight into Caffeine-Oxalic Cocrystal Dissociation in Formulations: Role of Excipients.
    Duggirala NK; Vyas A; Krzyzaniak JF; Arora KK; Suryanarayanan R
    Mol Pharm; 2017 Nov; 14(11):3879-3887. PubMed ID: 28990387
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Formulation-dependent stability mechanisms affecting dissolution performance of directly compressed griseofulvin tablets.
    Maclean N; Khadra I; Mann J; Abbott A; Mead H; Markl D
    Int J Pharm; 2023 Jan; 631():122473. PubMed ID: 36493970
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Development and in vitro evaluation of pH-independent release matrix tablet of weakly acidic drug valsartan using quality by design tools.
    Saydam M; Takka S
    Drug Dev Ind Pharm; 2018 Dec; 44(12):1905-1917. PubMed ID: 29969042
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vitro Controlled Release from Solid Pharmaceutical Formulations of two new Adamantane Aminoethers with Antitubercular Activity (I).
    Vlachou M; Siamidi A; Diamantidi E; Iliopoulou A; Papanastasiou I; Ioannidou V; Kourbeli V; Foscolos AS; Vocat A; Cole ST; Karalis V; Kellici T; Mavromoustakos T
    Drug Res (Stuttg); 2017 Aug; 67(8):447-450. PubMed ID: 28561241
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Continuous, simultaneous cocrystallization and formulation of Theophylline and 4-Aminobenzoic acid pharmaceutical cocrystals using twin screw melt granulation.
    Shaikh R; Walker GM; Croker DM
    Eur J Pharm Sci; 2019 Sep; 137():104981. PubMed ID: 31295548
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmaceutical preformulation studies and paediatric oral formulations of sodium dichloroacetate.
    Lopalco A; Curci A; Lopedota A; Cutrignelli A; Laquintana V; Franco M; Denora N
    Eur J Pharm Sci; 2019 Jan; 127():339-350. PubMed ID: 30447284
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Polyethylene Oxide (PEO) Molecular Weight Effects on Abuse-Deterrent Properties of Matrix Tablets.
    Meruva S; Donovan MD
    AAPS PharmSciTech; 2019 Dec; 21(1):28. PubMed ID: 31858320
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sounding out stability of enteric coated dosage forms using Broadband Acoustic Resonance Dissolution Spectroscopy (BARDS).
    O'Mahoney N; Alfarsi A; O'Sullivan H; McSweeney S; Crean A; Fitzpatrick D
    Int J Pharm; 2021 Jun; 602():120614. PubMed ID: 33887391
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rapid Characterization of Formulated Pharmaceuticals Using Fast MAS
    Hirsh DA; Wijesekara AV; Carnahan SL; Hung I; Lubach JW; Nagapudi K; Rossini AJ
    Mol Pharm; 2019 Jul; 16(7):3121-3132. PubMed ID: 31095913
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Formulation Development Approach to Identify and Select Stable Ultra-High-Concentration Monoclonal Antibody Formulations With Reduced Viscosities.
    Whitaker N; Xiong J; Pace SE; Kumar V; Middaugh CR; Joshi SB; Volkin DB
    J Pharm Sci; 2017 Nov; 106(11):3230-3241. PubMed ID: 28668340
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Optimization and evaluation of modified release solid dosage forms using artificial neural network.
    Sheth TS; Acharya F
    Sci Rep; 2024 Jul; 14(1):16358. PubMed ID: 39014107
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Development and Validation of a Discriminatory Dissolution Method for Rifaximin Products.
    Dharani S; Barakh Ali SF; Afrooz H; Khan MA; Rahman Z
    J Pharm Sci; 2019 Jun; 108(6):2112-2118. PubMed ID: 30685397
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Characterization of new functionalized calcium carbonate-polycaprolactone composite material for application in geometry-constrained drug release formulation development.
    Wagner-Hattler L; Schoelkopf J; Huwyler J; Puchkov M
    Drug Dev Ind Pharm; 2017 Oct; 43(10):1669-1676. PubMed ID: 28481735
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Characterization of Prototype Gummy Formulations Provides Insight into Setting Quality Standards.
    Adeleke OA; Abedin S
    AAPS PharmSciTech; 2024 Jul; 25(6):155. PubMed ID: 38960983
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An Integrated Approach for High-Shear Wet Granulation (HSWG) Processing of TPGS-Based Formulations: Demonstration of Process Robustness through Experimental Design Conditions.
    Sotthivirat S; Ren J; Wasylaschuk W; Afanador N; Rosenberg K; Taggart RV; Skomski D; Brown C
    J Pharm Sci; 2021 Aug; 110(8):2934-2945. PubMed ID: 33794276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.